Dr. Sherri McFarland (Chemistry and Biochemistry) received supplemental funding from the NIH National Cancer Institute for the project “Immunomodulating Ruthenium Metal Complexes for Melanoma Photodynamic Therapy.”
The project seeks to develop a novel class of ruthenium compounds that can be activated with therapeutic wavelengths of light to eliminate primary tumors, inhibit disseminated disease, and prevent recurrence. According to the abstract, it is hypothesized that light-responsive drugs with these capabilities will be of use in the development of photodynamic therapy (PDT) for treating melanoma.
